The Long Road to NASH Therapeutics: Uncovering Valuable Insights
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Management Articles
Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.
Read MoreThe Long Road to NASH Therapeutics: Uncovering Valuable Insights
Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
NAFLD and Cardiovascular Diseases: What is The Link?
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Understanding Nash: Symptoms, Detection, And Treatment
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways.
Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
A brief introduction to the most promising pharmacological agents for NASH
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).